RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in PBT (Profit Before Tax) by 21% Y-o-Y and by 8% Q-o-Q for Q2 FY23, maintaining the upward trajectory in EBITDA margins, which improved from 22.5% to 23.0% Q-o-Q.

Revenue from operations at Rs. 134.79 crore registered a growth of 20% Y-o-Y and a growth of 5% Q-o-Q for Q2 FY23. For H1 FY23, the company posted a jump in PBT by 25% Y-o-Y and recorded EBITDA margin expansion from 22.6% to 22.8% Y-o-Y.

Revenue from operations at Rs. 263.72 crore registered a growth of 19% Y-o-Y for H1 FY23.

Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs. Revenue and PBT grew by a healthy 20% and 21% respectively Y-o-Y. EBITDA margin retained its upward trajectory growing from 22.5% to 23.0% Q-o-Q."

"Domestic Formulations business has recorded a robust growth both in value and volumes - significantly and consistently ahead of the market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising newer and progressive segments is also witnessing an impressive uptake," commented Sikri.

"Our foray into Rheumatology has strengthened our Specialty segment. Salesforce productivity continues to register healthy upward momentum across business segments. International Formulations business has shown robust growth while API business has also picked up growth momentum. Our relentless focus on achieving cost efficiencies in our operations and eye on sales hygiene is helping us to consistently improve our margins. We are on course to implement our Transformation Agenda to achieve our strategic goals,” added Sikri.